Table 1 Clinicopathological characteristics of the surgical cohort.
Clinicopathological characteristics of the primary disease | ||||||
|---|---|---|---|---|---|---|
n | ‘any d-HGP’ | ‘pure r-HGP’ | OR | CI 95% | p | |
Menopausal status (post- vs pre-menopausal) | 1.75 | 0.78–4.00 | 0.175 | |||
Post-menopausal | 42 | 19 (33.3) | 23 (50.0) | |||
Pre-menopausal | 61 | 38 (66.7) | 23 (50.0) | |||
Missing | 30 | 17 | 13 | |||
Age (>50 vs ≤50 years) | 0.76 | 0.34–1.66 | 0.501 | |||
≤50 | 68 | 36 (60.0) | 32 (69.6) | |||
>50 | 38 | 24 (40.0) | 14 (30.4) | |||
Missing | 27 | 14 | 13 | |||
cT (>1 vs 1) | 1.20 | 0.44–3.42 | 0.729 | |||
1 | 20 | 12 (23.1) | 8 (20.0) | |||
2 | 52 | 27 (51.9) | 25 (62.5) | |||
3 | 17 | 11 (21.1) | 6 (15) | |||
4 | 3 | 2 (3.8) | 1 (2.5) | |||
Missing | 33 | 18 | 15 | |||
cN (≥1 vs 0) | 1.17 | 0.47–2.93 | 0.734 | |||
0 | 46 | 27 (51.9) | 19 (47.5) | |||
1 | 37 | 21 (40.4) | 16 (40.0) | |||
2 | 8 | 3 (5.8) | 5 (12.5) | |||
3c | 1 | 1 (1.9) | 0 (0.0) | |||
Missing | 41 | 22 | 19 | |||
cM (1 vs 0) | 1.08 | 0.39–2.95 | 0.880 | |||
0 | 57 | 35 (68.6) | 22 (71.0) | |||
1 | 25 | 16 (31,4) | 9 (29.0) | |||
Missing | 51 | 23 | 28 | |||
pN (1 vs 0) | 2.16 | 0.73–6.95 | 0.162 | |||
0 | 26 | 16 (47.1) | 10 (30.3) | |||
1 | 41 | 18 (52.9) | 23 (69.7) | |||
Missing | 66 | 40 | 26 | |||
Histological subtype (ILC vs NST) | 0.88 | 0.30–2.61 | 0.818 | |||
invasive ductal adenocarcinoma (NST) | 106 | 59 (85.5) | 47 (85.4) | |||
invasive lobular adenocarcinoma (ILC) | 17 | 9 (13.0) | 8 (14.5) | |||
Mucinous adenocarcinoma | 1 | 1 (1.5) | 0 (0.0) | |||
Missing | 9 | 5 | 4 | |||
Histological grade (2 and 3 vs 1) | 0.95 | 0.29–3.11 | 0.926 | |||
1 | 11 | 6 (11.8) | 5 (16.7) | |||
2 | 50 | 30 (58.8) | 20 (66.7) | |||
3 | 16 | 12 (23.5) | 4 (13.3) | |||
Missing | 56 | 26 | 30 | |||
Laterality (right vs left) | 2.24 | 1.00–5.12 | 0.049 | |||
Bilateral | 8 | 6 (9.4) | 2 (4.3) | |||
Left | 61 | 40 (62.5) | 21 (45.7) | |||
Right | 41 | 18 (28.1) | 23 (50.0) | |||
Missing | 23 | 10 | 13 | |||
ER status (positive vs negative) | 1.63 | 0.57–5.08 | 0.364 | |||
Negative | 18 | 12 (18.2) | 6 (12.2) | |||
Positive | 97 | 54 (81.8) | 43 (87.7) | |||
Missing | 18 | 8 | 10 | |||
HER2 status (amplified vs non-amplified) | 0.76 | 0.25–2.16 | 0.607 | |||
Non-amplified | 89 | 49 (81.7) | 40 (85.1) | |||
Amplified | 18 | 11 (18.3) | 7 (14.9) | |||
Missing | 26 | 14 | 12 | |||
Neoadjuvant chemotherapy (yes vs no) | 0.73 | 0.26–1.98 | 0.545 | |||
No | 76 | 43 (69.4) | 33 (80.5) | |||
Yes | 27 | 19 (30.6) | 8 (19.5) | |||
Missing | 30 | 12 | 18 | |||
Clinicopathological characteristics of liver metastasis | ||||||
|---|---|---|---|---|---|---|
ER-status (positive vs negative) | 0.71 | 0.30–1.68 | 0.439 | |||
Negative | 28 | 14 (20.0) | 14 (25.0) | |||
Positive | 98 | 56 (80,0) | 42 (75,0) | |||
Missing | 7 | 4 | 3 | |||
HER2 status (amplified vs non-amplified) | 0.87 | 0.35–2.10 | 0.758 | |||
Non-amplified | 100 | 54 (77.1) | 46 (80.7) | |||
Amplified | 27 | 16 (22.9) | 11 (19.3) | |||
Missing | 6 | 4 | 2 | |||
Extrahepatic metastasis (yes vs no) | 2.93 | 0.96–9.58 | 0.060 | |||
No | 94 | 58 (90.6) | 36 (76.6) | |||
Yes | 17 | 6 (9.4) | 11 (23.4) | |||
Missing | 22 | 10 | 12 | |||
Time between BC diagnosis and liver surgery (continuous) | 1.00 | 1.00–1.00 | 0.430 | |||
<1 month | 27 | 18 (28.6) | 9 (19.1) | |||
<1 year | 8 | 7 (11.1) | 1 (2.1) | |||
<2 years | 11 | 7 (11.1) | 4 (8.5) | |||
≥2 years | 65 | 31 (49.2) | 34 (70.2) | |||
Missing | 22 | 11 | 11 | |||
Systemic preoperative treatment before liver surgery (yes vs no) | 0.41 | 0.17–0.96 | 0.039 | |||
No | 34 | 12 (16.2) | 22 (37.3) | |||
Yes | 99 | 62 (83.8) | 37 (62.7) | |||
First site of progression (liver vs other) | 1.52 | 0.42–5.45 | 0.513 | |||
Liver (only) | 86 | 50 (87.7) | 36 (81.8) | |||
Liver and bone | 2 | 0 (0.0) | 2 (4.5) | |||
Liver, bone, and brain | 1 | 0 (0.0) | 1 (2.3) | |||
Other | 12 | 7 (12.3) | 5 (11.4) | |||
Unknown | 32 | 17 | 15 | |||
